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OBJECTIVES This study was initiated to identify the disease-causing genetic defect in a family with
hypertrophic cardiomyopathy (HCM) and high incidence of sudden death.
BACKGROUND Familial hypertropic cardiomyopathy (FHC) is an autosomal dominant transmitted disorder
that is genetically and clinically heterogeneous. Mutations in 11 genes have been associated
with the pathogenesis of the disease.
METHODS We studied a large FHC family, first by linkage analysis, to identify the gene involved, and
subsequently screened the gene, encoding alpha-tropomyosin (TPM1), for mutations by
using single-strand conformation polymorphism and sequencing analysis.
RESULTS Twelve family members presented clinical features of HCM, five of whom died at young age,
while others had only mild clinical features. Marker analysis showed linkage for the TPM1
gene on chromosome 15q22 (maximal logarithm of the odds score is 5.16,   0);
subsequently, a novel missense mutation (Glu62Gln) was identified.
CONCLUSIONS The novel mutation identified in TPM1 is associated with the clinical features of cardiac
hypertrophy in all but one genetically affected member of this large family. The clinical data
suggest a malignant phenotype at young age with a variable clinical manifestation and
penetrance at older age. The Glu62Gln mutation is the sixth TPM1 mutation identified as
the cause of FHC, indicating that mutations in this gene are very rare. This is the first
reported amino acid substitution at the f-position within the coiled-coil structure of the
tropomyosin protein. (J Am Coll Cardiol 2003;41:981–6) © 2003 by the American College
of Cardiology Foundation
Familial hypertrophic cardiomyopathy (FHC) is a clini-
cally and genetically heterogeneous disease with an au-
tosomal dominant mode of inheritance. Main clinical
features are increased left ventricular (LV) and/or right
ventricular muscle mass often in combination with asym-
metric hypertrophy of the septum. On echocardiography,
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an increased cardiac muscle thickness (13 mm or more) is
observed (1). Typical complaints include chest pain
(angina pectoris), shortness of breath (dyspnoea), fatigue,
palpitations, and syncope. Sudden cardiac death may be
the first dramatic symptom of the disease. The motion
and contraction force of striated cardiac muscle cells is
generated within the sarcomere by interaction between
thick and thin filaments. Impaired relaxation and con-
traction force, a hallmark of FHC is generally caused by
mutations in one of the sarcomere encoding genes. Until
now, 11 genes have been reported as being involved in the
development of FHC (2– 4). A total of 10 of the 11 genes
encode cardiac proteins that assemble into contractile
units (sarcomeres) of the cardiomyocytes. The genes that
encode beta-cardiac myosin heavy chain (MYH7), myo-
sin binding protein C (MYBPC3), and troponin T
(TNNT2) account for approximately 75% of FHC (based
on reported mutations). Recently, the gene PRKAG2
(gamma 2 subunit of AMP-activated protein kinase)
encoding a non-sarcomeric protein on chromosome 7q
was found to be involved in cardiac hypertrophy (5,6). In
these patients, a complex of symptoms including conduc-
tion disturbances and Wolf-Parkinson-White syndrome
was demonstrated, probably related to glycogen storage
(7,8).
In this paper we describe a large five-generation FHC
family from the Netherlands. Linkage was identified with
the alfa tropomyosin (TPM1) gene, and a novel mutation
Glu62Gln (E62Q) was detected. The TPM1 gene is a very
rare cause of FHC (approximately 5%), except for the
Finnish population where TPM1 mutations account for
11% (9). Until now, only eight missense mutations have
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been described within the TPM1 gene causing either
hypertrophic (FHC) or dilated cardiomyopathy (DCM)
(10–17). The presence of the new mutation was associated
with variable clinical features, although the mutation should
be considered malignant, especially at younger age.
METHODS
Clinical studies. A large five-generation Dutch family
with FHC was analyzed in our institute. Family members
were clinically evaluated by physical examination, two-
dimensional echocardiographic examination, and 12-lead
electrocardiography (ECG) analysis. Histopathological data
of deceased family members were obtained when available.
The clinical diagnosis of hypertrophic cardiomyopathy
(HCM) was made if the interventricular septal thickness
was 13 mm, in the absence of other cardiac or systemic
causes of LV hypertrophy. In some family members, phe-
notypic assignment of cardiomyopathy was based on his-
topathological features of HCM at postmortem examina-
tion. Informed consent was obtained from each family
member for genetic analysis.
Genetic studies. MARKER ANALYSIS. Blood samples were
collected from 22 individuals (clinically affected members
and family members with no clinical symptoms of cardiac
hypertrophy). Genomic DNA was extracted according to
standard protocols (18). Marker sets, used to test four
candidate genes, were either located in the 5 and 3
flanking regions of the genes or were intragenic. D1S2716
and D1S2622 at 2 to 2.5 centiMorgan (cM) proximal of the
troponin T gene (TNNT2; chromosome 1q32), marker
D11S1344 and D11S1357 at 0.8 cM of the myosin binding
protein C gene (MYBPC3; chromosome 11p11.2), two
intragenic markers MYOI and MYOII for the beta-myosin
heavy chain (MYH7; chromosome 14q12), and, finally,
D15S159 and D15S993 at 0.5 cM for the alpha tropo-
myosin gene (TPM1; chromosome 15q22) (19–22). Mark-
ers were derived from the Genome Database (GDB) and
Genethon, labeled with fluorescent dyes and polymerase
chain reaction amplified according to standard procedures.
Fragment length analysis was performed by using the
ABI3100 fragment gene analysis system (Applied Bio-
systems Inc., Nieuwerkerk a/d IJsel, the Netherlands) and
Genescan analysis software version 3.7 (Applied Biosystems
Inc.).
LINKAGE ANALYSIS. Linkage analysis was performed by
using the ILINK module of the LINKAGE program
version 5.1 (23). Disease penetrance was estimated at 75%
and disease frequency at 0.2%.
MUTATION ANALYSIS. Nine exons (1a, 2b, 3, 4, 5, 6b, 7, 8,
and 9a, b), comprising the entire coding sequence of the
TPM1 gene in cardiac muscle, were amplified by using
intronic primers as previously described (10). Single-strand
conformation polymorphism analysis was performed at 5°C
and 15°C, and amplicons with aberrant conformers were
purified and analyzed by sequencing as described previously
(24). For diagnostic analysis, the mutation detection was
performed by MnlI endonuclease (Roche, Almere, the
Netherlands) of the PCR product of exon 2b and analyzed
by gel electrophoresis on a 3% Nusieve Agarose gel (FMC,
Sanvertech, Boechout, Belgium).
RESULTS
Clinical characteristics. The pedigree of the FHC family
is presented in Figure 1, and main clinical characteristics are
presented in Table 1. The family came to our attention
because of the early sudden death of a mother (III.11) and
four of her children (IV:16, IV:17, IV:18, and IV:19). The
cause of her death was unclear, and no autopsy was
performed. Postmortem evaluation of the two children
(IV:16, IV:17) revealed severe asymmetric septal hypertro-
phy. Histology indicated myofibrillar disarray with intersti-
tial fibrosis in the apical part of the septum and abnormal
intramural coronary vessels. The third son (IV:8) was
examined after the death of the oldest two sibs. He suddenly
died at age 15. The youngest son (IV:19) was examined at
age 17, and, at that time, he complained about fatigue. A
few months later, he died suddenly. The father of this
family remarried to a younger sister (III:13) of his first wife.
Two children (IV:21 and IV:22) again showed HCM at age
33 and 35 years, respectively. Besides cardiac abnormalities,
both were mentally retarded suffered spastic paralysis. The
origin of their mental deficiency remains unclear. Their
mother remained without complaints at age 67 years. She
was frequently reinvestigated and did not show any signs of
HCM on ECG or two-dimensional echocardiography.
Only on magnetic resonance imaging investigation a septal
hypertrophy (max, 17 mm) was found. In the other branch
of this family, the diagnosis HCM was made for individual
IV:9 at routine screening for military services. At age 7, his
daughter (V:3) was investigated for signs of HCM. Elec-
trocardiographic examination and echocardiography dem-
onstrated signs of LV hypertrophy. At present she remains
without complaints.
Linkage of the TPM1 gene. Because of maternal trans-
mission in the right part of the pedigree (Fig. 1), HCM-
related and specific mitochondrial DNA mutations
(A3243G, A3260G, C3303T, A4300G, A4269G,
A43417G, G8344A, and T8993C/G) were excluded, as
well as mitochondrial DNA deletions (data not shown).
Abbreviations and Acronyms
cM  centiMorgan
DCM  dilated cardiomyopathy
FHC  familial hypertrophic cardiomyopathy
HCM  hypertrophic cardiomyopathy
LV  left ventricular
MYBPC  myosin binding protein C
MYH7  beta-cardiac myosin heavy chain
TNNT2  troponin T
TPM1  alpha-tropomyosin
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Marker analysis of 20 family members and two spouses of
deceased members excluded the involvement of the MYH7,
the MYBPC3, and the TNNT2 genes. Segregation of the
alfa-tropomyosin (TPM1) markers were in line with a
possible involvement of the TPM1 gene. Linkage analysis
software revealed a maximum LOD score Z() 5.16 (
0) for markers D15S159 and D15S993. Subsequently, nine
amplified exons of the TPM1 gene were screened by SSCP
analysis. An aberrant conformer was identified in exon 2b
indicating a sequence variation. Sequence analysis showed a
GAG to CAG transition at position 184 (complementary
DNA reference sequence of TPM1, Genebank accession
number M19713). The nucleotide substitution changes the
amino acid glutamic acid of codon 62 into glutamine
(Glu62Gln). In this family, the missense mutation segre-
gated with the disease. As the G to C substitution abolishes
a MnlI restriction site, we applied MnlI restriction analysis
to identify carriers of the genetic defect in all family
members at risk. The pathogenicity of the mutation was
based on exclusion of the mutation within a control group of
100 unrelated subjects (200 chromosomes) and by the
localization of the substituted amino acid in an evolutionary
highly conserved domain of the alpha-tropomyosin protein.
DISCUSSION
Familial HCM is a clinically and genetically heterogeneous
disorder. Incomplete penetrance and variable age-related
clinical expression is often observed within and between
families, even if an identical mutation is involved. At the
moment, mutations in 11 genes have been identified that
are involved in FHC, making linkage analysis the first step
in identifying the genetic defect, as has been demonstrated
in this family. In FHC families, however, a major problem
is the high incidence of sudden death of affected family
members and, because of that, no tissue or DNA is available
for linkage studies. In this study, marker analysis showed
statistically significant linkage with the TPM1 gene on
chromosome15q22, and the causative mutation was identi-
fied in all clinically affected family members. The high
conservation of the protein domain involved, and the
absence in the control population, indicated that this mu-
tation was very likely the cause of FHC in this family.
However, in this pedigree, the penetrance of the Glu62Gln
mutation is incomplete, as one of the carriers with the
mutation presents only with very mild hypertrophy at older
age that might be missed by routine echocardiographic
screening (Fig, 1; individual III:13). These findings suggest
that other genetic or environmental factors, yet unidentified,
must be involved in modifying the effect of the mutation
between family members. The clinical presentation of the
novel mutation points towards a malignant (high incidence
of sudden death) form of FHC with varying hypertrophy
from mild to severe, in particular, asymmetrical septal
hypertrophy. An interesting finding is the coronary abnor-
malities encountered during autopsy in patient IV:16. De-
spite marked initial thickening, there were no signs of old or
fresh myocardial infarction. In addition, the localization of
the fibrosis was not related to the site of coronary abnor-
malities. These findings make coronary disease a less likely
cause of sudden death in this patient. In contrast, the
extensive disarray combined with fibrosis and maybe local
subendocardial ischemia could provide an arrhythmic sub-
strate. Unfortunately, no serial measurements or Holter
monitoring were performed in affected family members. No
cases presented with HCM progressing into DCM.
Up to the present, only few TPM1 mutations have been
reported, causing either hypertrophic (FHC) or DCM. Two
mutations in exon 5, near the Ca2-dependent troponin-T
Figure 1. Five generation pedigree of the familial hypertrophic cardiomyopathy family. Pedigree symbols: squares  males; circles  females; symbols
with diagonal slash  deceased family members; filled symbols  individuals with documented hypertrophic cardiomyopathy; dot within symbol 
obligate carrier of the genetic defect; unfilled symbols  individuals without cardiac hypertrophy. Underneath the symbols are indicated the age (years)
of sudden death and the genetically defined carriers of the mutation with E62Q (Glu62Gln). Bars  the haplotypes and numbers the alleles length (in
basepairs) of the markers D15S159 (upper) and D15S993 (lower); filled bars  the risk haplotype 165 to 181.
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Table 1. Clinical Features of the HCM Family
Pedigree Gender Age E62Q Clinical History
2D Echo
ECG RemarksLVEF SH PW ESD EDD Others
II.2 F ()* SCD at 69 yrs NA NA Obligate carrier
II.4 F () NA NA Obligate carrier;
gynecological cancer at
age 71 yrs
III.4 F () SCD at 47 yrs NA NA Obligate carrier
III.5 M () SCD at 45 yrs NA NA Obligate carrier
III.11 F ? () SCD at 35 yrs NA NA Obligate carrier
III.13 F 67 † No complaints Normal Normal MRI: ASH 17 mm‡
IV.3 M 46  No complaints 66% 16 14 23 41 LVH, abnormal ST-segments
IV.7 F 34  Atypical complaints Normal NA
IV.8 M 44  PAF 64% 18 8 30 46 SAM, MI
IV.9 M 34  PAF, dyspnea 70% 14 10 33 55 SAM, MI LVH, abnormal ST-segments
IV.11 M 18 () SCD at 18 yrs,
arrhythmia
NA 31 10 24 38 SAM LVH, abnormal ST-segments Died during catheterization
IV.16 M 19 () SCD at 19 yrs NA NA PM: septal hypertrophy,
myofibrillar disarray 
fibrosis
IV.17 F 17 () SCD at 17 yrs NA LVH PM: extensive septal
hypertrophy  LVH,
RVH, myofibrillar
disarray  fibrosis
IV.18 M 15 () SCD at 15 yrs 50% 15 10 NA NA LVH, abnormal ST-segments
IV.19 M 17 () SCD at 17 yrs,
fatigue
50% 24 13 NA NA LVH, abnormal ST-segments,
sinus bradycardia
PM: muscle degeneration,
interstitial fibrosis
IV.21 M 35  No complaints 70% 18 12 29 49 Abnormal ST-segments Mentally retarded spasticity
IV.22 M 33  No complaints 50% 18 Normal 21 38 MI LVH, abnormal ST-segments Mentally retarded spasticity
V.3 F 12  No complaints 20 LVH, abnormal ST-segments Hypertrophy at age 5 yrs
*The () symbol indicates possible carrier of the mutation Glu62Gln; †the  symbol indicates carrier of the mutation Glu62Gln; ‡MRI: normal value 12 mm.
Age  age (yr) at cardiac evaluation; ASH  asymmetrical septum hypertrophy; EDD  end-diastolic diameter; ESD  end-systolic diameter; HCM  hypertrophic cardiomyopathy; LVH  left ventricular hypertrophy; LVEF
 left ventricular ejection fraction; MI  mitral incompetence; MRI  magnetic resonance imaging; NA  not available; PAF  paroxysmal atrial fibrillation; PM  post mortem; PW  posterial wall; RVH  right ventricular
hypertrophy; SAM  systolic anterior movement of the mitral valve; SCD  sudden cardiac death; SH  septum hypertrophy.
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binding domain of the alpha-tropomyosin protein, have
been associated with a transition from severe hypertrophy to
DCM (Glu180Val) and with mild LV hypertrophy but
poor prognosis (Glu180Gly) (10,15). Within the same
protein domain, a mutational hot spot at position
Asp175Asn has been identified in five unrelated families
(four Caucasian, one Japanese) with FHC (9,10,12,13). The
Asp175Asn mutation was studied in three families with full
penetrance and seemed to be associated with a favorable
prognosis (25). Unique features of mild cardiac hypertrophy
with a high mortality rate were described for the mutation
Val95Ala in exon 3 (16). The mutations Glu40Lys and
Glu54Lys in exon 2b occurred in an area that may alter the
binding of alpha-tropomyosin to actin and have been
associated with clinical features of DCM (17).
The TPM1 gene encodes a rigid rod-shaped protein.
This protein is abundantly expressed in the striated muscle
cells and various other tissues and forms a double helix
coiled-coil structure by head-to-tail polymerization. Several
isoforms result from the TPM1 gene by alternative splicing,
and the adult cardiac isoform is encoded by only nine of the
14 exons. The protein is located within the thin filament of
the sarcomere where it is associated with actin by twisting
around the long axis of the actin filament as a coiled-coil
dimer. It can bind seven consecutive actin monomers and,
so, contributes to the stability of the thin filament (26).
Another thin filament component troponin T also has a
binding site for tropomyosin. This binding site is thought to
be responsible for positioning the troponin complex, which
is composed of three polypeptides, troponin T, I, and C,
into the thin filament. The troponin-tropomyosin complex
is Ca2-sensitive. By raising the level of free calcium, the
position of the tropomyosin-troponin complex is shifted,
and the actin filaments can interact with the myosin heads
of the thick filaments, which are active in the contracting
muscle.
Our findings suggest that differences in clinical presen-
tation may depend on the location of the amino acid
substitution in the TPM1 helix. The novel mutation
Glu62Gln is the most 5 proximal missense mutation that
has been reported in the TPM1 gene thus far, and which is
associated with a malignant form of FHC.
The negative-charged polar amino acid is replaced by an
uncharged polar residue at a position on the outer surface of
the coiled-coil (26). In the coiled-coil filament of the
tropomyosin molecule, the positions of the amino acids are
arranged in an order of highly conserved heptad repeats
along the entire length of the TPM1 protein (26,27). All
mutations that have been reported previously and associated
with FHC have occurred at the g-, d-, or e-position of the
heptad repeat (Fig. 2). The altered amino acids, which have
been correlated with DCM, only occurred at the e-position.
Two of the DCM-associated mutations change the acidic
amino acid residue into a basic residue. Olson et al. (17)
suggested that these mutations create a locally increased
positive charge in the negatively charged surface of tropo-
myosin, changing the electrostatic interactions between
actin and tropomyosin filaments. This novel Glu62Gln
mutation is the first reported amino acid substitution at the
f-position within the coiled-coil that changes the polarity of
the amino acid and which is associated with hypertrophy.
Further, it should be noticed that the amino acid variants at
the positions 62, 63, and 70 are located within a protein
domain with a function yet unidentified.
Reports of novel mutations within the TPM1 gene may
help to unravel and define functionally important domains
that are crucial for specific interaction with other (sarcomer-
ic) proteins. Preliminary data of mutated amino acids in
specific regions might indicate in which way the cardiomy-
opathy might develop, hypertrophy or dilation of the cardiac
ventricles. By identifying the important domains for either
disorder, better diagnostic and prognostic tools become
available. Furthermore, the knowledge will help to elucidate
the complex architecture of the sarcomere.
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